Get started
Author

Amanda J. Long

Observed names: A LONG, A. J. Long, A. Long, Amanda Long
Observed institutions: Eli Lilly (United States), IQVIA (United Kingdom), IQVIA (United States), Taiho Oncology (United States), Australian and New Zealand Urogenital and Prostate Cancer Trials Group, UCLouvain
ORCID: 0009-0005-7307-3934
Observed ORCID: 0009-0005-7307-3934
OpenAlex ID: A5055671933
Disposition and Metabolic Fate of Atomoxetine Hydrochloride: The Role of CYP2D6 in Human Disposition and Metabolism
2003 · John-Michael Sauer, G. Douglas Ponsler, et al. · Drug Metabolism and Disposition · 153
Atomoxetine Pharmacokinetics in Children and Adolescents with Attention Deficit Hyperactivity Disorder
2003 · Jennifer W. Witcher, Amanda Long, et al. · Journal of Child and Adolescent Psychopharmacology · 116
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites
2003 · Stephan A. Chalon, Jean‐Pierre Desager, et al. · Clinical Pharmacology & Therapeutics · 64
Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome
2004 · John-Michael Sauer, Amanda J. Long, et al. · Journal of Pharmacology and Experimental Therapeutics · 55
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele
2007 · Yi M. Cui, Choo H. Teng, et al. · British Journal of Clinical Pharmacology · 41
Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
2021 · Emmanuel Chigutsa, Lisa O’Brien, et al. · Clinical Pharmacology & Therapeutics · 39
PDF
Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men
2011 · A. Matsui, J. Azuma, et al. · The Journal of Clinical Pharmacology · 37
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder
2009 · Philip Hazell, Katja Becker, et al. · ADHD Attention Deficit and Hyperactivity Disorders · 28
PDF
Relative Contributions of Presystemic and Systemic Peptidases to Oral Exposure of a Novel Metabotropic Glutamate 2/3 Receptor Agonist (LY404039) After Oral Administration of Prodrug Pomaglumetad Methionil (LY2140023)
2014 · William F. Annes, Amanda Long, et al. · Journal of Pharmaceutical Sciences · 21
Population Pharmacokinetics of Necitumumab in Cancer Patients
2016 · Amanda Long, Emmanuel Chigutsa, et al. · Clinical Pharmacokinetics · 19
PDF
In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1
2016 · Y. Anne Pak, Amanda J. Long, et al. · Drug Metabolism and Disposition · 15
PDF
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings
2020 · Mansoor Saleh, Philippe A. Cassier, et al. · The Oncologist · 10
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
2021 · Ling Gao, Yiu-Keung Lau, et al. · Cancer Chemotherapy and Pharmacology · 9
PDF
Prediction of the Renal Organic Anion Transporter 1 (OAT1)- Mediated Drug Interactions for LY404039, the Active Metabolite of Pomaglumetad Methionil
2023 · Y. Anne Pak, Maria M. Posada, et al. · Pharmaceutical Research · 7
Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm
2023 · Lan Ni, Azhar Zaman Khan, et al. · Clinical Pharmacology & Therapeutics · 6
PDF
Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia
2015 · Wei Zhang, Malcolm I. Mitchell, et al. · International Journal of Clinical Pharmacology and Therapeutics · 6
A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
2024 · Amanda Long, Ikuo Yamamiya, et al. · Clinical and Translational Science · 5
PDF
Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
2019 · Ronald De Wit, Thomas Powles, et al. · Journal of Clinical Oncology · 3
Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB.
2018 · Jaffer A. Ajani, Anghel Adrian Udrea, et al. · Journal of Clinical Oncology · 3
A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
2017 · J.A. Ajani, A. Udrea, et al. · Annals of Oncology · 3
PDF
Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
2017 · Junning Cao, Dongmei Ji, et al. · The Oncologist · 3
PDF
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
2023 · Himanshu P. Upadhyaya, Jenny Y. Chien, et al. · Infectious Diseases and Therapy · 2
PDF
Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
2021 · Seiichiro Mitani, Yucherng Chen, et al. · PubMed · 2
Ramucirumab (RAM) exposure-response (ER) relationship in RANGE, a randomized phase III trial of docetaxel (DOC) with or without RAM in advanced urothelial carcinoma (UC) patients (pts) who progressed on or after platinum therapy.
2018 · Ronald De Wit, Thomas Powles, et al. · Journal of Clinical Oncology · 2
Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study
2019 · M. Saleh, P. Cassier, et al. · Annals of Oncology · 1
Works count: 30
Citation count: 648
H-index: 11
I10-index: 12
Year
Topic
Type